
Craig D. Ricci
Examiner (ID: 6907, Phone: (571)270-5864 , Office: P/1628 )
| Most Active Art Unit | 1628 |
| Art Unit(s) | 1611, 1628, 1614 |
| Total Applications | 1601 |
| Issued Applications | 776 |
| Pending Applications | 153 |
| Abandoned Applications | 697 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18270459
[patent_doc_number] => 20230091701
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => METHODS OF TREATING HEPATIC ENCEPHALOPATHY
[patent_app_type] => utility
[patent_app_number] => 17/682624
[patent_app_country] => US
[patent_app_date] => 2022-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43321
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17682624
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/682624 | Methods of treating hepatic encephalopathy | Feb 27, 2022 | Issued |
Array
(
[id] => 17655506
[patent_doc_number] => 20220175971
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => DYE ENHANCED VISUALIZATION OF CATARACT SURGERY
[patent_app_type] => utility
[patent_app_number] => 17/682711
[patent_app_country] => US
[patent_app_date] => 2022-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6499
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17682711
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/682711 | DYE ENHANCED VISUALIZATION OF CATARACT SURGERY | Feb 27, 2022 | Abandoned |
Array
(
[id] => 18034535
[patent_doc_number] => 20220378750
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/680782
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17122
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680782
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/680782 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | Feb 24, 2022 | Abandoned |
Array
(
[id] => 18404573
[patent_doc_number] => 20230165924
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-01
[patent_title] => Herbal Formulation for the Prevention and Management of COVID-19 by Regulating Immunomodulatory Properties
[patent_app_type] => utility
[patent_app_number] => 17/681368
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4824
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17681368
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/681368 | Herbal Formulation for the Prevention and Management of COVID-19 by Regulating Immunomodulatory Properties | Feb 24, 2022 | Abandoned |
Array
(
[id] => 17655554
[patent_doc_number] => 20220176019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => POROUS POLYMER SCAFFOLD AND METHODS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/679796
[patent_app_country] => US
[patent_app_date] => 2022-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4921
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17679796
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/679796 | POROUS POLYMER SCAFFOLD AND METHODS THEREOF | Feb 23, 2022 | Abandoned |
Array
(
[id] => 19140391
[patent_doc_number] => 20240139170
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => TOPICAL FORMULATIONS OF A JAK 1/3 INHIBITOR AND METHODS OF USE THEREOF FOR TREATMENT OF ATOPIC DERMATITIS AND OTHER SKIN CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 18/277886
[patent_app_country] => US
[patent_app_date] => 2022-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15631
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18277886
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/277886 | TOPICAL FORMULATIONS OF A JAK 1/3 INHIBITOR AND METHODS OF USE THEREOF FOR TREATMENT OF ATOPIC DERMATITIS AND OTHER SKIN CONDITIONS | Feb 17, 2022 | Pending |
Array
(
[id] => 17640516
[patent_doc_number] => 20220168254
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => PARENTERAL NUTRITION FORMULATION WITH OPTIMIZED AMINO ACID AND GLUCOSE CONTENT
[patent_app_type] => utility
[patent_app_number] => 17/670728
[patent_app_country] => US
[patent_app_date] => 2022-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10216
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17670728
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/670728 | PARENTERAL NUTRITION FORMULATION WITH OPTIMIZED AMINO ACID AND GLUCOSE CONTENT | Feb 13, 2022 | Pending |
Array
(
[id] => 20413009
[patent_doc_number] => 12496271
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-16
[patent_title] => Oral cannabinoid formulations
[patent_app_type] => utility
[patent_app_number] => 17/670733
[patent_app_country] => US
[patent_app_date] => 2022-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10003
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17670733
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/670733 | Oral cannabinoid formulations | Feb 13, 2022 | Issued |
Array
(
[id] => 19423810
[patent_doc_number] => 12083201
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-10
[patent_title] => Compositions comprising solvent, a monoalcohol, glycerin, and thickener
[patent_app_type] => utility
[patent_app_number] => 17/591075
[patent_app_country] => US
[patent_app_date] => 2022-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 5063
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17591075
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/591075 | Compositions comprising solvent, a monoalcohol, glycerin, and thickener | Feb 1, 2022 | Issued |
Array
(
[id] => 17830045
[patent_doc_number] => 20220267349
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => HETEROCYCLIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/588816
[patent_app_country] => US
[patent_app_date] => 2022-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23393
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17588816
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/588816 | HETEROCYCLIC COMPOUNDS | Jan 30, 2022 | Abandoned |
Array
(
[id] => 19142119
[patent_doc_number] => 20240140943
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5
[patent_app_type] => utility
[patent_app_number] => 18/263052
[patent_app_country] => US
[patent_app_date] => 2022-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21021
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 299
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18263052
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/263052 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | Jan 25, 2022 | Pending |
Array
(
[id] => 17702773
[patent_doc_number] => 20220202779
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => ORAL PREPARATION OF GLUCOKINASE ACTIVATOR AND PREPARATION METHOD THEREFOR
[patent_app_type] => utility
[patent_app_number] => 17/584951
[patent_app_country] => US
[patent_app_date] => 2022-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18106
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 141
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17584951
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/584951 | ORAL PREPARATION OF GLUCOKINASE ACTIVATOR AND PREPARATION METHOD THEREFOR | Jan 25, 2022 | Abandoned |
Array
(
[id] => 17593444
[patent_doc_number] => 20220143017
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DIABETIC NEPHROPAPHY INCLUDING ADENOSINE DERIVATIVE
[patent_app_type] => utility
[patent_app_number] => 17/585497
[patent_app_country] => US
[patent_app_date] => 2022-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4770
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 116
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17585497
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/585497 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DIABETIC NEPHROPAPHY INCLUDING ADENOSINE DERIVATIVE | Jan 25, 2022 | Pending |
Array
(
[id] => 19955292
[patent_doc_number] => 12325698
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-10
[patent_title] => Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
[patent_app_type] => utility
[patent_app_number] => 17/583841
[patent_app_country] => US
[patent_app_date] => 2022-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12304
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17583841
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/583841 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | Jan 24, 2022 | Issued |
Array
(
[id] => 17748181
[patent_doc_number] => 20220226384
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => EXTRACELLULAR VESICLE COMPOSITIONS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/579482
[patent_app_country] => US
[patent_app_date] => 2022-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16983
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17579482
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/579482 | EXTRACELLULAR VESICLE COMPOSITIONS AND METHODS OF USE THEREOF | Jan 18, 2022 | Abandoned |
Array
(
[id] => 19127150
[patent_doc_number] => 20240132503
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => SALT FORM AND CRYSTAL FORM OF PYRAZOLE SUBSTITUTED IMIDAZO[1,2- A]QUINOXALINE DERIVATIVE
[patent_app_type] => utility
[patent_app_number] => 18/264061
[patent_app_country] => US
[patent_app_date] => 2022-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11964
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18264061
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/264061 | Salt form and crystal form of pyrazole substituted imidazo[1,2-a]quinoxaline derivative | Jan 11, 2022 | Issued |
Array
(
[id] => 19550215
[patent_doc_number] => 12133907
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-05
[patent_title] => Lipophilic third generation retinoid
[patent_app_type] => utility
[patent_app_number] => 17/570851
[patent_app_country] => US
[patent_app_date] => 2022-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2476
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17570851
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/570851 | Lipophilic third generation retinoid | Jan 6, 2022 | Issued |
Array
(
[id] => 18255958
[patent_doc_number] => 20230082997
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/571018
[patent_app_country] => US
[patent_app_date] => 2022-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 60731
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17571018
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/571018 | Cereblon ligands and bifunctional compounds comprising the same | Jan 6, 2022 | Issued |
Array
(
[id] => 19947084
[patent_doc_number] => 12318422
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-03
[patent_title] => Tannin-based antiproliferative pharmaceutical
[patent_app_type] => utility
[patent_app_number] => 17/569182
[patent_app_country] => US
[patent_app_date] => 2022-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 18
[patent_no_of_words] => 10458
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 162
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17569182
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/569182 | Tannin-based antiproliferative pharmaceutical | Jan 4, 2022 | Issued |
Array
(
[id] => 19142120
[patent_doc_number] => 20240140944
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/269609
[patent_app_country] => US
[patent_app_date] => 2021-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23021
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 649
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18269609
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/269609 | NOVEL NAPHTHYRIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE AND USE THEREOF | Dec 28, 2021 | Pending |